

**April 2024 PDL/DUR Board Meeting Minutes**

**Date:** April 17, 2024

**Members Present:** Barnhill, Blake, Brown, Caldwell, Jost, McGrane, Nauts, Oley, Putsch

**Members Absent:** Anglim, Blank, Stone

**Board Member Update:** The Board was introduced to Erin Oley. Erin joins the DUR Board as the nurse practitioner representative.

**Others Present:** Shannon Sexauer, Dani Feist, Katie Hawkins (DPHHS); Kathy Novak (Magellan); Bahny, Miranda, Zody (Mountain Pacific); and representatives from the pharmaceutical industry.

**Public Comment:** Speaker information is as follows:

- Erin Nowak, AbbVie – Rinvoq®
- Hiten Patadia, Incyte – Opzelura®
- Tara McKinley, Madrigal Pharmaceuticals – Rezdifra®
- Christine Dube, AstraZeneca – Fasenra®
- Nicholas Bires, Lilly – Omvoh® Pen

Written public comment was submitted to the Board prior to the meeting. It consisted of five manufacturer documents regarding Cosentyx®, Eplclusa®, Opzelura®, Rezdifra®, and Simlandi®. The Board had no comments on these medications. Ian McGrane requested additional information from the AbbVie representative regarding head-to-head trials of Rinvoq with other products in the class.

**Meeting Minute Review:** The meeting minutes from the March 13, 2024, PDL meeting were approved as written.

**Department Update:** None

**PREFERRED DRUG LIST MEETING**

Results of the Board review of Group 3 (Red category):

<b>CLASS</b>	<b>DRUG NAME</b>	<b>2024 RECOMMENDATIONS</b>	<b>Grandfathered</b>
ACNE AGENTS	ND - Cabtreo®	BENZOYL PEROXIDE COMBOS - Class effect. BENZOYL PEROXIDE AGENTS - Class effect. CLINDAMYCIN AGENTS - Class effect. SODIUM SULFACETAMIDE AGENTS - Class effect. TOPICAL RETINOIDS & COMBOS - Class effect. ERYTHROMYCIN TOPICAL - Class effect.	No
ANTIBIOTICS, GI	ND - Vowst®, Likmez®	Must have metronidazole and vancomycin.	No

CLASS	DRUG NAME	2024 RECOMMENDATIONS	Grandfathered
CYTOKINES & CAM ANTAGONIST	ND - Bimzelx®, Omvoh® Pen  NI - Cibinqo®, Cosentyx®, Enbrel®, Entyvio®, Orencia®, Rinvoq®, adalimumab biosimilars, infliximab biosimilar	Therapeutic alternatives. Do not add anakinra (Kineret®) due to inferior efficacy and increased toxicity. Grandfather.	Yes
GLUCOCORTICOIDS, INHALED	ND - Airsupra®  NI - Breo Ellipta®	Class effect. Must have 1 HFA option ( <i>new add</i> ).	No
GLUCOCORTICOIDS, ORAL	ND - Agamree® <i>Agamree was tentatively added to the agenda, but the State has opted to remove oral glucocorticoid agents with a sole DMD indication from the PDL and manage with clinical criteria alone.</i>	SHORT ACTING - cortisone, hydrocortisone - Therapeutic alternatives. INTERMEDIATE ACTING - methylprednisolone, prednisone, and prednisolone - Therapeutic alternatives, must include a dosepak. LONG ACTING - betamethasone, dexamethasone - Therapeutic alternatives. BUDESONIDE - Must have 1 budesonide.  <i>Remove deflazacort from PDL class but continue to manage with clinical criteria.</i>	No
IMMUNOMODULATORS, ATOPIC DERMATITIS	NI - Adbry®, Dupixent®, Zorvy®	Therapeutic alternatives. Continue PA criteria.	No

The Board reviewed the blue category in advance of the meeting. Kathy from Magellan reported on new generics, updated indications, and drug availability changes in this category. This category of drugs has no new clinically significant information since the last review. Board recommendations for Group 2 (Blue category) from 2023 were retained with an adjustment to the Bladder Relaxants class. The recommendations are as follows:

CLASS	2024 RECOMMENDATIONS	Grandfathered
ANTI-ALLERGENS, ORAL	Continue with PA criteria.	No
ANTIBIOTICS, INHALED	Therapeutic alternatives.	No
ANTIBIOTICS, TOPICAL	Must have a mupirocin product.	No
ANTIBIOTICS, VAGINAL	Therapeutic alternatives.	No

<b>CLASS</b>	<b>2024 RECOMMENDATIONS</b>	<b>Grandfathered</b>
ANTIFUNGALS, ORAL	Must have terbinafine and fluconazole. Must have 1 of clotrimazole or nystatin. Continue PA criteria on ketoconazole.	No
ANTIFUNGALS, TOPICAL	Therapeutic alternatives for approved indications.	No
ANTIHISTAMINES, MINIMALLY SEDATING	Class effect. Must have 1 single ingredient agent.	No
ANTINEOPLASTIC AGENTS, TOPICAL	Therapeutic alternatives.	No
ANTIPARASITICS, TOPICAL	Therapeutic alternatives. Continue PA criteria.	No
ANTIPSORIATICS, TOPICAL	Class effect. Must have 1 topical formulation and a scalp formulation. Continue PA criteria.	No
ANTIVIRALS, ORAL (HSV/INFLUENZA)	HSV Antivirals - Class effect. INFLUENZA Antivirals - Must have both oseltamivir and baloxavir marboxil.	No
ANTIVIRALS, TOPICAL	Class effect.	No
BLADDER RELAXANTS	Class effect. Must have 1 long-acting agent (either by half-life or dosage form), 1 anticholinergic ( <i>new add</i> ), and 1 beta-3 receptor agonist ( <i>new add</i> ).	No
BPH AGENTS	ALPHA BLOCKERS - Class effect. ANDROGEN HORMONE INHIBITORS/COMBOS - Class effect. PDE-5 for BPH - Tadalafil will be non-preferred. Continue with PA criteria.	No
BRONCHODILATORS, BETA AGONISTS	BETA AGONIST, LONG-ACTING - Class effect. BETA AGONIST, SHORT-ACTING - Class effect.	No
CEPHALOSPORINS & RELATED AGENTS	2 <sup>nd</sup> GENERATION - Class effect. 3 <sup>rd</sup> GENERATION - Class effect.	No
COPD AGENTS	Class effect. Must have a nebulizer product and a long-acting combination product.	No
EPINEPHRINE, SELF-INJECTED	Class effect.	No
FLUOROQUINOLONES, ORAL	2 <sup>nd</sup> GENERATION - Class effect. Must have ciprofloxacin. 3 <sup>rd</sup> GENERATION - Class effect.	No
HEPATITIS C AGENTS	RIBAVIRINS - Class effect. PEGYLATED INTERFERONS - Do not add. ALL OTHERS - Therapeutic alternatives. Must have a pangenotypic agent. Continue with existing PA criteria. Grandfather.	Yes
IMMUNOMODULATORS, ASTHMA	Therapeutic alternatives. Grandfathered class.	Yes
IMMUNOMODULATORS, TOPICAL	Therapeutic alternatives.	No

<b>CLASS</b>	<b>2024 RECOMMENDATIONS</b>	<b>Grandfathered</b>
IMMUNOSUPPRESSANTS	Must have an entity of azathioprine, cyclosporine, mycophenolate, sirolimus, and tacrolimus. Grandfather.	Yes
INTRANASAL RHINITIS AGENTS	NASAL STEROIDS - Class effect. NASAL ANTIHISTAMINES & OTHERS - Class effect.	No
LEUKOTRIENE MODIFIERS	Must have montelukast.	No
MACROLIDES & KETOLIDES	Class effect. Must have azithromycin, clarithromycin, and erythromycin.	No
METHOTREXATE AGENTS	Must have 1 oral and 1 injectable agent.	No
ROSACEA AGENTS, TOPICAL	Must have 1 metronidazole product.	No
SMOKING CESSATION	Must have a nicotine patch and either nicotine gum or lozenge. Must have varenicline.	No
STERIODS, TOPICAL	LOW, MEDIUM, HIGH, and VERY HIGH POTENCY CLASSES - Class effect for each class; must have 1 cream and 1 ointment from each category.	No
TETRACYCLINES	Must have doxycycline.	No

There were no Group 1 (green category) drugs to review.

The meeting was adjourned at 2:15 p.m.

The final PDL meeting for 2024 will be held on May 22, 2024, at 1:00 p.m., in this same format.